Regeneration originates from putative stem cells residing in the ductal compartment from which complete recovery is induced within a week after ductal obstruction [5] [7].
This resulted in a dataset of 80 complete genomes, 73 of which had CDS features specified from which complete proteomes could be determined.
Polycarpic woody plants develop terminal or axillary buds with embryonic shoots from which complete branches can develop after specific signals [ 1].
In our previous studies [ 13- 15, 35, 36], we have reported the benefit of using hair shaft as a source of enriched, pure mtDNA, from which complete mitochondrial genomes can be rapidly sequenced using the Roche FLX technology.
We thus considered a novel approach to sequence new ascidian mt genomes: Illumina sequencing of mixed total genomic extracts, followed by a single assembly run from which complete mt genomes are identified among all assembled contigs.
Reliable estimates of sequence polymorphism for rapidly evolving genes, and in-depth characterization of the selective pressures governing their evolution, will require de novo genome assemblies from which complete gene sequences can be extracted and analyzed.
Compared to the extinct moas from which complete mtDNAs have previously been determined from non-permafrost specimens [ 23], the cave bear genome extends the time frame by an order of magnitude, showing that complete mtDNA analysis can be performed using a wide range of samples.
A phylogeny including the bat species from which complete PV genome sequences have been retrieved was constructed using a concatenation of partial sequences from three mitochondrial markers, namely Cytochrome Oxidase I (COI, 592 bp), Cytochrome b (Cytb, 754 bp), and NADH dehydrogenase (ND1, 518 bp), and the nuclear gene recombination activating gene (RAG2, 759 bp).
In such circumstances, it has been argued that troponin may 'leak' from the myocyte cytosol into the bloodstream without causing significant damage or that these small troponin elevations represent an amount of myocyte necrosis/apoptosis from which complete recovery may be expected [ 99].
Eligible subjects were female carriers of deleterious mutations in BRCA1 or BRCA2 aged ≥18 years from which complete information about year of birth, mutation description, age at last follow-up, ages at breast and or ovarian cancer diagnosis and age or date of prophylactic mastectomy was available (Antoniou et al, 2008).
